* From the story…
Over the last 15 years, the labor force participation rate fell more in counties where more opioids were prescribed. Here’s a county-by-county look at the relationship between the change in the labor force participation rate at the state level and the opioid prescription rate at the county level […]
Krueger notes that, “Regardless of the direction of causality, the opioid crisis and depressed labor force participation are now intertwined in many parts of the U.S.” He argues that finding a solution to the decades-long slide in labor force participation by prime-age men should be “a national priority.” Men who are outside the workforce, he writes, express very low levels of subjective well-being and report deriving relatively little meaning from their daily activities. […]
Because nearly half of this group [men who are out of the labor force] reported being in poor health, it may be possible for expanded health insurance coverage and preventative care under the Affordable Care Act to positively affect the health of prime age men going forward. The finding that nearly half of NLF [not in the labor force] prime age men take pain medication on a daily basis and that 40 percent report that pain prevents them from accepting a job suggests that pain management interventions could potentially be helpful.
*** UPDATE *** Ugh…
The drug company founder now charged with leading a nationwide conspiracy to bribe doctors and pharmacists to overprescribe an opioid cancer pain drug once was listed among Arizona’s richest billionaires.
John N. Kapoor, the founder of Insys Therapeutics, several years ago was listed by Forbes as having a worth of $2.4 billion. That worth has fallen amid the indictments of numerous fellow Insys executives, but Forbes still listed Kapoor’s worth at $1.75 billion on Thursday as he went to U.S. federal court in the fraud and racketeering case.
Kapoor is also the longtime chairman of the board of Akorn Pharmaceuticals, headquartered in Lake Forest. Akorn is in the process of being acquired by German health care company Fresenius Kabi for $4.3 billion. That deal is expected to close by early next year, subject to regulatory approval. […]
The new indictment alleges Kapoor and the other defendants offered bribes to doctors to write large numbers of prescriptions for the fentanyl-based pain medication that is meant only for cancer patients with severe pain. Most people who received prescriptions did not have cancer.